Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and α- and β-catenin mRNA expressions

Jiro Fujimoto, Satoshi Ichigo, Masashi Hori, Shigeo Morishita, Teruhiko Tamaya
In: The Journal of Steroid Biochemistry and Molecular Biology · 1996 · vol. 57(5-6) , pp. 275–282 · doi:10.1016/0960-0760(95)00281-2 · PMID:8639463 · W2066098545
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This study investigated the effects of progestins and danazol on cell-to-cell adhesion and the mRNA expression of E-cadherin and α- and β-catenin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The first step of invasion and metastasis is the detachment of cancer cells in the primary tumor, which is mainly controlled by the function in the adherens junction, consisting of E-cadherin associated proteins (E-cadherin, alpha- and beta-catenins, vinculin, alpha-actinin, and actin). The cell-to-cell aggregation activity and the expressions of E-cadherin, and alpha- and beta-catenin mRNAs in Ishikawa cells of well-differentiated endometrial cancer were significantly suppressed by estrogen. These suppressions were reversed by progesterone, medroxyprogesterone acetate (MPA) and danazol. Proteins in the adherens junction appeared to be expressed intact and to be functional in Ishikawa cells. Persistent estrogen predominant milieu might contribute to the detachment of well-differentiated endometrial cancer cells, leading to spreading of those cells, while progestins and danazol protect estrogen-induced spreading of those cells.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

References (39)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-11T05:51:57.177246+00:00
unpaywall
last seen: 2026-09-23T06:15:37.550144+00:00
License: CC0 · commercial use OK